Today, the Pharmaceutical Benefits Scheme (PBS) expanded its listing for Evrysdi (Risdiplam) to include pre-symptomatic babies with three copies of the SMN2 gene.
This is excellent news for these infants, as they now have three available treatment options following the PBS listings of Zolgensma in October 2023 and Spinraza in March 2024. These advancements significantly enhance the treatment landscape for SMA and offer hope for better outcomes.
Join a powerful community of supporters who are helping tackle spinal muscular atrophy at its very core. Our community relies on us for support and best-practice resources to guide them in living well with SMA, as well as for resources to help raise disease awareness, educate others and advocate for people living with SMA in the wider Australian community.
